Viking Therapeutics Inc. (VKTX)
NASDAQ: VKTX
· Real-Time Price · USD
28.71
-0.16 (-0.55%)
At close: May 01, 2025, 3:59 PM
28.55
-0.56%
After-hours: May 01, 2025, 04:20 PM EDT
-0.55% (1D)
| Bid | 27.91 |
| Market Cap | 3.22B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -128.24M |
| EPS (ttm) | -1.16 |
| PE Ratio (ttm) | -24.75 |
| Forward PE | -13.36 |
| Analyst | Buy |
| Ask | 28.8 |
| Volume | 2,916,966 |
| Avg. Volume (20D) | 4,858,508 |
| Open | 28.91 |
| Previous Close | 28.87 |
| Day's Range | 27.69 - 29.01 |
| 52-Week Range | 18.92 - 81.86 |
| Beta | 0.83 |
About VKTX
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also deve...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 28, 2015
Employees 45
Stock Exchange NASDAQ
Ticker Symbol VKTX
Analyst Forecast
According to 13 analyst ratings, the average rating for VKTX stock is "Buy." The 12-month stock price forecast is $96, which is an increase of 234.38% from the latest price.
Stock Forecasts2 days ago
+7.71%
Viking Therapeutics shares are trading higher afte...
Unlock content with
Pro Subscription
2 weeks ago
+10.58%
Viking Therapeutics shares are trading higher after Pfizer discontinued the development of danuglipron.
